<DOC>
	<DOCNO>NCT00629642</DOCNO>
	<brief_summary>A clinical study evaluate efficacy safety solifenacin patient bladder symptom due spinal cord injury multiple sclerosis</brief_summary>
	<brief_title>Clinical Study Solifenacin Succinate Patients With Bladder Symptoms Due Spinal Cord Injury Multiple Sclerosis</brief_title>
	<detailed_description>A clinical study compare efficacy safety solifenacin succinate patient neurogenic detrusor overactivity . In randomized , double blind , double dummy study solifenacin compare placebo active comparator , oxybutynin hydrochloride . Patients randomize one four treatment arm ; solifenacin 10mg , solifenacin 5mg , placebo oxybutynin 15mg . Patients assess four week treatment period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Spinal Cord Diseases</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Written inform consent obtain Subjects neurogenic detrusor overactivity due : Multiple sclerosis ( MS ) ( EDSS≤8 ) Spinal cord injury ( SCI ) ( partial complete lesion ) MS SCI symptom stable &gt; = 6 month Neurogenic detrusor overactivity symptom stable &gt; = 6 month Subject willing able perform clean , intermittent , catheterization , require Subject willing able take study medication compliance protocol Subjects neurogenic detrusor overactivity due Parkinson 's cerebrovascular disease Subjects Sjögren 's Syndrome similar symptom Subjects evidence symptomatic urinary tract infection , chronic inflammation interstitial cystitis , bladder stone , previous pelvic radiation therapy previous current malignant disease pelvic organs Subjects stress incontinence mixed incontinence stress predominant factor determine investigator Subjects evidence pressure sores &gt; = grade 2 Subjects history bladder sphincterotomy Subjects know history vesicoureteral reflux without upper urinary tract infection Any clinically significant condition , opinion investigator make subject unsuitable study include history acute urinary retention , severe gastrointestinal obstruction ( include paralytic ileus intestinal atony ) , severe gastrointestinal condition ( include toxic megacolon ulcerative colitis ) , myasthenia gravis , narrow angle glaucoma shallow anterior chamber Subjects undergoing hemodialysis Subjects severe hepatic impairment Concurrent use drug intend treat symptom overactive bladder Use antidepressant muscle relaxant administer constant dose &gt; = 3 month Use nondrug treatment intend treat overactive bladder symptom include electrostimulation therapy , botulinum toxin vanilloids therapy six month prior commencement study Use permanent , indwell catheter Known suspect hypersensitivity solifenacin succinate , oxybutynin hydrochloride , anti cholinergics lactose Concomitant use strong CYP3A4 inhibitor , e.g . ketoconazole Pregnant woman , woman intend become pregnant study , woman childbearing potential sexually active practice unreliable method birth control woman lactate study . Reliable contraceptive method intrauterine device , contraceptive pill combination type , hormonal implant injectable contraceptive Participation clinical study within 30 day randomization , limit set national law , whichever long Employees Astellas Group , third party associate study , study site Subjects maximum bladder capacity &gt; = 400ml visit 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Neurogenic bladder</keyword>
	<keyword>Vesicare</keyword>
</DOC>